Erratum (DOI:10.1016/S1470-2045(08)70098-6);Evidence behind use of intensity-modulated radiotherapy: a systematic review of comparative clinical studies

The Lancet Oncology

Volumn 9, Issue 4, 2008, Pages 367-375

  Veldeman, Liv ^a   Madani, Indira ^a   Hulstaert, Frank ^b   De Meerleer, Gert ^a   Mareel, Marc ^a   De Neve, Wilfried ^a  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

^b BELGIAN HEALTH CARE KNOWLEDGE CENTRE KCE   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; FLUOROURACIL; GEMCITABINE; MITOMYCIN;

ANUS CARCINOMA; ASTROCYTOMA; BLINDNESS; BLOOD TOXICITY; BONE MARROW SUPPRESSION; BRACHYTHERAPY; BREAST CANCER; BREAST FIBROSIS; CANCER CONTROL; CENTRAL NERVOUS SYSTEM TUMOR; CLINICAL TRIAL; DIGESTIVE SYSTEM CANCER; DISEASE FREE SURVIVAL; DRY EYE; ENDOMETRIUM CANCER; ESOPHAGITIS; EVIDENCE BASED MEDICINE; EXTERNAL BEAM RADIOTHERAPY; GASTROINTESTINAL TOXICITY; GLIOBLASTOMA; GYNECOLOGIC CANCER; HEAD AND NECK CANCER; HUMAN; HYPOPHARYNX CANCER; INTENSITY MODULATED RADIATION THERAPY; LUNG CANCER; LUNG NON SMALL CELL CANCER; LUNG RESECTION; MASTECTOMY; MEDULLOBLASTOMA; MOUTH CANCER; NASOPHARYNX CANCER; NOSE CANCER; OPTIC NERVE DISEASE; OROPHARYNX CANCER; OTOTOXICITY; OVERALL SURVIVAL; PANCREAS CANCER; PLEURA MESOTHELIOMA; PRIORITY JOURNAL; PROSTATE CANCER; QUALITY OF LIFE; RADIATION DOSE DISTRIBUTION; RADIATION DOSE FRACTIONATION; RADIATION INJURY; RADIATION PNEUMONIA; RECTUM HEMORRHAGE; REVIEW; SEXUAL FUNCTION; SKIN TOXICITY; SQUAMOUS CELL CARCINOMA; SYSTEMATIC REVIEW; UROGENITAL TRACT DISEASE; UTERINE CERVIX CANCER; VISUAL IMPAIRMENT; XEROSTOMIA;

EID: 40949149466     PISSN: 14702045     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1470-2045(08)70140-2     Document Type: Erratum

References (75)

1. Levels of Evidence for Human Studies of Cancer Complementary and Alternative Medicine (PDQ®). http://www.cancer.gov/cancertopics/pdq/levels-evidence-cam/healthprofessional/ (accessed Feb 29, 2008).
2. Pignol J., Olivotto I., Rakovitch E., et al. Phase III randomized study of intensity modulated radiation therapy versus standard wedging technique for adjuvant breast radiotherapy. Int J Radiat Oncol Biol Phys 66 3 suppl 1 (2006) S1
3. Al-Sarraf M., LeBlanc M., Giri P., et al. Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized Intergroup Study 0099. J Clin Oncol 16 (1998) 1310-1317
4. Pow E., Kwong D., McMillan A., et al. Xerostomia and quality of life after intensity-modulated radiotherapy vs conventional radiotherapy for early-stage nasopharyngeal carcinoma: initial report on a randomized controlled clinical trial. Int J Radiat Oncol Biol Phys 66 (2006) 981-991
5. Wolden S., Chen W., Pfister D., Kraus D., Berry S., and Zelefsky M. Intensity-modulated radiation therapy (IMRT) for nasopharynx cancer: update of the Memorial Sloan-Kettering experience. Int J Radiat Oncol Biol Phys 64 (2006) 57-62
6. Eisbruch A., Rhodus N., Rosenthal D., et al. How should we measure and report radiotherapy-induced xerostomia?. Semin Radiat Oncol 13 (2003) 226-234
7. Fang F., Tsai W., Chen H., et al. Intensity-modulated or conformal radiotherapy improves the quality of life of patients with nasopharyngeal carcinoma: comparisons of four radiotherapy techniques. Cancer 109 (2007) 313-321
8. Hsiung C., Ting H., Huang H., Lee C., Huang E., and Hsu H. Parotid-sparing intensity-modulated radiotherapy (IMRT) for nasopharyngeal carcinoma: preserved parotid function after IMRT on quantitative salivary scintigraphy, and comparison with historical data after conventional radiotherapy. Int J Radiat Oncol Biol Phys 66 (2006) 454-461
9. Dulguerov P., Jacobsen M., Allal A., Lehmann W., and Calcaterra T. Nasal and paranasal sinus carcinoma: are we making progress? A series of 220 patients and a systematic review. Cancer 92 (2001) 3012-3029
10. Porceddu S., Martin J., Shanker G., et al. Paranasal sinus tumors: Peter MacCallum Cancer Institute experience. Head Neck 26 (2004) 322-330
11. Hoppe B., Stegman L., Zelefsky M., et al. Treatment of nasal cavity and paranasal sinus cancer with modern radiotherapy techniques in the postoperative setting-the MSKCC experience. Int J Radiat Oncol Biol Phys 67 (2007) 691-702
12. Duthoy W., Boterberg T., Claus F., et al. Postoperative intensity-modulated radiotherapy in sinonasal carcinoma: clinical results in 39 patients. Cancer 104 (2005) 71-82
13. Chen A., Daly M., Bucci M., et al. Carcinomas of the paranasal sinuses and nasal cavity treated with radiotherapy at a single institution over five decades: are we making improvement?. Int J Radiat Oncol Biol Phys 69 (2007) 141-147
14. Chao K., Majhail N., Huang C., Simpson J., Perez C., and Haughey B. Intensity-modulated radiation therapy reduces late salivary toxicity without compromising tumor control in patients with oropharyngeal carcinoma: a comparison with conventional techniques. Radiother Oncol 61 (2001) 275-280
15. Lee N., de Arruda F., Puri D., Wolden S., Narayana A., and Mechalakos J. A comparison of intensity-modulated radiation therapy and concomitant boost radiotherapy in the setting of concurrent chemotherapy for locally advanced oropharyngeal carcinoma. Int J Radiat Oncol Biol Phys 66 (2006) 966-974
16. Milano M., Vokes E., Kao J., et al. Intensity-modulated radiation therapy in advanced head and neck patients treated with intensive chemoradiotherapy: preliminary experience and future directions. Int J Oncol 28 (2006) 1141-1151
17. Rades D., Fehlauer F., Wroblesky J., Albers D., Schild S., and Schmidt R. Prognostic factors in head-and-neck cancer patients treated with surgery followed by intensity-modulated radiotherapy (IMRT), 3D-conformal radiotherapy, or conventional radiotherapy. Oral Oncology 43 (2007) 535-543
18. Studer G., Zwahlen R., Graetz K., Davis B., and Glanzmann C. IMRT in oral cavity cancer. Radiat Oncol 2 (2007) 16
19. Rothschild S., Studer G., Seifert B., et al. PET/CT with intensity-modulated radiotherapy (IMRT) improves treatment outcome of locally advanced pharyngeal carcinoma: a matched-pair analysis. Radiat Oncol 2 (2007) 22
20. Jabbari S., Kim H., Feng M., et al. Matched case-control study of quality of life and xerostomia after intensity-modulated radiotherapy or standard radiotherapy for head-and-neck cancer: initial report. Int J Radiat Oncol Biol Phys 63 (2005) 725-731
21. Pacholke H., Amdur R., Morris C., et al. Late xerostomia after intensity-modulated radiation therapy versus conventional radiotherapy. Am J Clin Oncol 28 (2005) 351-358
22. Daly M., Lieskovsky Y., Pawlicki T., et al. Evaluation of patterns of failure and subjective salivary function in patients treated with intensity modulated radiotherapy for head and neck squamous cell carcinoma. Head Neck 29 (2007) 211-220
23. Braam P., Terhaard C., Roesink J., and Raaijmakers C. Intensity-modulated radiotherapy significantly reduces xerostomia compared with conventional radiotherapy. Int J Radiat Oncol Biol Phys 66 (2006) 975-980
24. Münter M., Hoffner S., Hof H., et al. Changes in salivary gland function after radiotherapy of head-and-neck tumors measured by quantitative pertechnetate scintigraphy: comparison of intensity-modulated radiotherapy and conventional radiation therapy with and without amifostine. Int J Radiat Oncol Biol Phys 67 (2007) 651-659
25. Graff P., Lapeyre M., Desandes E., et al. Impact of intensity-modulated radiotherapy on health-related quality of life for head and neck cancer patients: matched-pair comparison with conventional radiotherapy. Int J Radiat Oncol Biol Phys 67 (2007) 1309-1317
26. Yao M., Karnell L., Funk G., Lu H., Dornfeld K., and Buatti J. Health-related quality-of-life outcomes following IMRT versus conventional radiotherapy for oropharyngeal squamous cell carcinoma. Int J Radiat Oncol Biol Phys 69 (2007) 1354-1360
27. Peeters S., Heemsbergen W., Koper P., et al. Dose-response in radiotherapy for localized prostate cancer: results of the Dutch multicenter randomized phase III trial comparing 68 Gy of radiotherapy with 78 Gy. J Clin Oncol 24 (2006) 1990-1996
28. Pollack A., Zagars G., Starkschall G., et al. Prostate cancer radiation dose response: results of the M. D. Anderson phase III randomized trial. Int J Radiat Oncol Biol Phys 53 (2002) 1097-1105
29. Zietman A., DeSilvio M., Slater J., et al. Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: a randomized controlled trial. JAMA 294 (2005) 1233-1239
30. Boersma L., van den Brink M., Bruce A., et al. Estimation of the incidence of late bladder and rectum complications after high-dose (70-78 Gy) conformal radiotherapy for prostate cancer, using dose-volume histograms. Int J Radiat Oncol Biol Phys 41 (1998) 83-92
31. Koper P., Heemsbergen W., Hoogeman M., et al. Impact of volume and location of irradiated rectum wall on rectal blood loss after radiotherapy of prostate cancer. Int J Radiat Oncol Biol Phys 58 (2004) 1072-1082
32. Vargas C., Martinez A., Kestin L., et al. Dose-volume analysis of predictors for chronic rectal toxicity after treatment of prostate cancer with adaptive image-guided radiotherapy. Int J Radiat Oncol Biol Phys 62 (2005) 1297-1308
33. Vavassori V., Fiorino C., Rancati T., et al. Predictors for rectal and intestinal acute toxicities during prostate cancer high-dose 3D-CRT: results of a prospective multicenter study. Int J Radiat Oncol Biol Phys 67 (2007) 1401-1410
34. Sanguineti G., Cavey M., Endres E., et al. Does treatment of the pelvic nodes with IMRT increase late rectal toxicity over conformal prostate-only radiotherapy to 76 Gy?. Strahlenther Onkol 182 (2006) 543-549
35. Kupelian P., Thakkar V., Khuntia D., Reddy C., Klein E., and Mahadevan A. Hypofractionated intensity-modulated radiotherapy (70 gy at 2.5 Gy per fraction) for localized prostate cancer: long-term outcomes. Int J Radiat Oncol Biol Phys 63 (2005) 1463-1468
36. Kupelian P., Reddy C., Carlson T., Altsman K., and Willoughby T. Preliminary observations on biochemical relapse-free survival rates after short-course intensity-modulated radiotherapy (70 Gy at 2.5 Gy/fraction) for localized prostate cancer. Int J Radiat Oncol Biol Phys 53 (2002) 904-912
37. Brenner D., and Hall E. Fractionation and protraction for radiotherapy of prostate carcinoma. Int J Radiat Oncol Biol Phys 43 (1999) 1095-1101
38. Vora S., Wong W., Schild S., Ezzell G., and Halyard M. Analysis of biochemical control and prognostic factors in patients treated with either low-dose three-dimensional conformal radiation therapy or high-dose intensity-modulated radiotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys 68 (2007) 1053-1058
39. Zelefsky M., Fuks Z., Hunt M., et al. High dose radiation delivered by intensity modulated conformal radiotherapy improves the outcome of localized prostate cancer. J Urol 166 (2001) 876-881
40. Zelefsky M., Fuks Z., Happersett L., et al. Clinical experience with intensity modulated radiation therapy (IMRT) in prostate cancer. Radiother Oncol 55 (2000) 241-249
41. Jani A., Gratzie J., and Correa D. Influence of intensity-modulated radiotherapy on acute genitourinary and gastrointestinal toxicity in the treatment of localized prostate cancer. Technol Cancer Res Treat 6 (2007) 11-15
42. Jani A., Su A., Correa D., and Gratzle J. Comparison of late gastrointestinal and genitourinary toxicity of prostate cancer patients undergoing intensity-modulated versus conventional radiotherapy using localized fields. Prostate Cancer Prostatic Dis 10 (2007) 82-86
43. Jani A., Su A., and Milano M. Intensity-modulated versus conventional pelvic radiotherapy for prostate cancer: analysis of acute toxicity. Urology 67 (2006) 147-151
44. Namiki S., Ishidoya S., Tochigi T., et al. Health-related quality of life after intensity modulated radiation therapy for localized prostate cancer: comparison with conventional and conformal radiotherapy. Jpn J Clin Oncol 36 (2006) 224-230
45. Kupelian P., Reddy C., Carlson T., and Willoughby T. Dose/volume relationship of late rectal bleeding after external beam radiotherapy for localized prostate cancer: absolute or relative rectal volume?. Cancer J 8 (2002) 62-66
46. Su A., and Jani A. Chronic genitourinary and gastrointestinal toxicity of prostate cancer patients undergoing pelvic radiotherapy with intensity-modulated versus 4-field technique. Am J Clin Oncol 30 (2007) 215-219
47. Ashman J., Zelefsky M., Hunt M., Leibel S., and Fuks Z. Whole pelvic radiotherapy for prostate cancer using 3D conformal and intensity-modulated radiotherapy. Int J Radiat Oncol Biol Phys 63 (2005) 765-771
48. Shu H., Lee T., Vigneauly E., et al. Toxicity following high-dose three-dimensional conformal and intensity-modulated radiation therapy for clinically localized prostate cancer. Urology 57 (2001) 102-107
49. Yoshimura K., Kamoto T., Nakamura E., et al. Health-related quality-of-life after external beam radiation therapy for localized prostate cancer: intensity-modulated radiation therapy versus conformal radiation therapy. Prostate Cancer Prostatic Dis 10 (2006) 288-292
50. Lips I., Dehnad H., Boeken Kruger A., et al. Health-related quality of life in patients with locally advanced prostate cancer after 76 Gy intensity-modulated radiotherapy vs 70 Gy conformal radiotherapy in a prospective and longitudinal study. Int J Radiat Oncol Biol Phys 69 (2007) 656-661
51. D'Amico A., Chen M., Oh-Ung J., et al. Changing prostate-specific antigen outcome after surgery or radiotherapy for localized prostate cancer during the prostate-specific antigen era. Int J Radiat Oncol Biol Phys 54 (2002) 436-441
52. Liebross R., Pollack A., Lankford S., von Eschenbach A., and Zagars G. Relationship of ultrasound staging and bilateral biopsy positivity to outcome in stage T1c prostate cancer treated with radiotherapy. Urology 52 (1998) 647-652
53. Pinover W., Hanlon A., Lee W., Kaplan E., and Hanks G. Prostate carcinoma patients upstaged by imaging and treated with irradiation. An outcome-based analysis. Cancer 77 (1996) 1334-1341
54. Chism D., Hanlon A., Troncoso P., Al-Saleem T., Horwitz E., and Pollack A. The Gleason score shift: score four and seven years ago. Int J Radiat Oncol Biol Phys 56 (2003) 1241-1247
55. Mundt A., Lujan A., Rotmensch J., et al. Intensity-modulated whole pelvic radiotherapy in women with gynaecologic malignancies. Int J Radiat Oncol Biol Phys 52 (2002) 1330-1337
56. Mundt A., Roeske J., Lujan A., et al. Initial clinical experience with intensity-modulated whole-pelvis radiation therapy in women with gynecologic malignancies. Gynecol Oncol 82 (2001) 456-463
57. Mundt A., Mell L., and Roeske J. Preliminary analysis of chronic gastrointestinal toxicity in gynecology patients treated with intensity-modulated whole pelvic radiation therapy. Int J Radiat Oncol Biol Phys 56 (2003) 1354-1360
58. Brixey C., Roeske J., Lujan A., Yamada S., Rotmensch J., and Mundt A. Impact of intensity-modulated radiotherapy on acute hematologic toxicity in women with gynecologic malignancies. Int J Radiat Oncol Biol Phys 54 (2002) 1388-1396
59. Chen M., Tseng C., Tseng C., Kuo Y., Yu C., and Chen W. Clinical outcome in posthysterectomy cervival cancer patients treated with concurrent cisplatin and intensity-modulated pelvic radiotherapy: comparison with conventional radiotherapy. Int J Radiat Oncol Biol Phys 67 (2007) 1438-1444
60. Fuller C., Choi M., Forthuber B., et al. Standard fractionation intensity modulated radiation therapy (IMRT) of primary and recurrent glioblastoma multiforme. Radiat Oncol 2 (2007) 26
61. Iuchi T., Hatano K., Narita Y., Kodama T., Yamaki T., and Osato K. Hypofractionated high-dose irradiation for the treatment of malignant astrocytomas using simultaneous integrated boost technique by IMRT. Int J Radiat Oncol Biol Phys 64 (2006) 1317-1324
62. Huang E., Teh B., Strother D., et al. Intensity-modulated radiation therapy for pediatric medulloblastoma: early report on the reduction of ototoxicity. Int J Radiat Oncol Biol Phys 52 (2002) 599-605
63. Poortmans P. Evidence based radiation oncology: breast cancer. Radiother Oncol 84 (2007) 84-101
64. Donovan E., Bleakley N., Denholm E., et al. Randomised trial of standard 2D radiotherapy (RT) versus intensity modulated radiotherapy (IMRT) in patients prescribed breast radiotherapy. Radiother Oncol 82 (2007) 254-264
65. Freedman G., Anderson P., Li J., et al. Intensity modulated radiation therapy (IMRT) decreases acute skin toxicity for women receiving radiation for breast cancer. Am J Clin Oncol 29 (2006) 66-70
66. Harsolia A., Kestin L., Grills I., et al. Intensity-modulated radiotherapy results in significant decrease in clinical toxicities compared with conventional wedge-based breast radiotherapy. Int J Radiat Oncol Biol Phys 68 (2007) 1375-1380
67. Yom S., Liao Z., Liu H., et al. Initial evaluation of treatment-related pneumonitis in advanced-stage non-small-cell lung cancer patients treated with concurrent chemotherapy and intensity-modulated radiotherapy. Int J Radiat Oncol Biol Phys 68 (2007) 94-102
68. Allen A., Czerminska M., Janne P., et al. Fatal pneumonitis associated with intensity-modulated radiation therapy for mesothelioma. Int J Radiat Oncol Biol Phys 65 (2006) 640-645
69. Ahamad A., Stevens C., Smythe W., et al. Promising early local control of malignant pleural mesothelioma following postoperative intensity modulated radiotherapy (IMRT) to the chest. Cancer J 9 (2003) 476-484
70. Crane C., Antolak J., Rosen I., et al. Phase I study of concomitant gemcitabine and IMRT for patients with unresectable adenocarcinoma of the pancreatic head. Int J Gastrointest Cancer 30 (2001) 123-132
71. Bai Y., Wu G., Guo W., et al. Intensity modulated radiation therapy and chemotherapy for locally advanced pancreatic cancer: results of feasibility study. World J Gastroenterol 9 (2003) 2561-2564
72. Ben-Josef E., Shields A., Vaishampayan U., et al. Intensity-modulated radiotherapy (IMRT) and concurrent capecitabine for pancreatic cancer. Int J Radiat Oncol Biol Phys 59 (2004) 454-459
73. Milano M., Chmura S., Garofalo M., et al. Intensity-modulated radiotherapy in treatment of pancreatic and bile duct malignancies: toxicity and clinical outcome. Int J Radiat Oncol Biol Phys 59 (2004) 445-453
74. Milano M., Jani A., Farrey K., Rash C., Heimann R., and Chmura S. Intensity-modulated radiation therapy (IMRT) in the treatment of anal cancer: toxicity and clinical outcome. Int J Radiat Oncol Biol Phys 63 (2005) 354-361
75. Esthappan J., Mutic S., Malyapa R., et al. Treatment planning guidelines regarding the use of CT/PET-guided IMRT for cervical carcinoma with positive paraaortic lymph nodes. Int J Radiat Oncol Biol Phys 58 (2004) 1289-1297